Table 1.
Cytokine | Control (pg/ml) | IP-10 (pg/ml) | Mig (pg/ml) | I-TAC (pg/ml) |
---|---|---|---|---|
IL-1ra | 1.8 ± 0.7 | 25.0 ± 2.1* | 3.8 ± 1.3 | 3.9 ± 0.9 |
IL-1β | 0.3 ± 0.1 | 6.5 ± 2.5* | 2.6 ± 1.0 | 1.8 ± 0.9 |
IL-2 | 0.0 ± 0.0 | 2.0 ± 0.1* | 0.1 ± 0.1 | 0.1 ± 0.0 |
IL-4 | 0.1 ± 0.0 | 1.1 ± 0.1* | 0.1 ± 0.0 | 0.1 ± 0.0 |
IL-5 | 0.0 ± 0.0 | 0.3 ± 0.1* | 0.0 ± 0.0 | 0.0 ± 0.0 |
IL-6 | 9.2 ± 4.9 | 80.5 ± 27.4* | 40.5 ± 17.4 | 29.5 ± 14.8 |
IL-7 | 0.1 ± 0.0 | 0.9 ± 0.1* | 0.2 ± 0.1 | 0.2 ± 0.0 |
IL-8 | 186.8 ± 89.8 | 404.7 ± 73.3* | 315.3 ± 79.7 | 251.7 ± 76.5 |
IL-9 | 1.1 ± 0.2 | 4.4 ± 0.4* | 1.8 ± 0.3 | 2.2 ± 0.3* |
IL-10 | 0.7 ± 0.2 | 2.1 ± 0.4* | 1.2 ± 0.4 | 1.7 ± 0.6 |
IL-12(p70) | 0.3 ± 0.1 | 0.9 ± 0.1* | 0.4 ± 0.1 | 0.3 ± 0.1 |
IL-13 | 1.1 ± 0.3 | 1.8 ± 0.2* | 1.4 ± 0.2 | 1.4 ± 0.2 |
IL-15 | 0.2 ± 0.0 | 0.5 ± 0.1* | 0.3 ± 0.1 | 0.3 ± 0.1 |
IL-17 | 0.8 ± 0.2 | 2.5 ± 0.7* | 0.6 ± 0.2 | 0.7 ± 0.4 |
Eotaxin | 1.7 ± 0.6 | 23.2 ± 0.5* | 2.4 ± 1.1 | 2.4 ± 0.9 |
FGF | 1.4 ± 0.5 | 5.6 ± 1.3* | 1.1 ± 0.6 | 3.1 ± 1.1 |
G-CSF | 0.2 ± 0.1 | 2.5 ± 0.4* | 0.5 ± 0.2 | 0.3 ± 0.2 |
GM-CSF | 0.8 ± 0.3 | 9.4 ± 1.0* | 1.6 ± 0.4 | 1.7 ± 0.5 |
IFN-γ | 2.6 ± 0.6 | 107.0 ± 10.3* | 5.4 ± 2.1 | 5.6 ± 2.0 |
MCP-1 | 32.6 ± 14.3 | 86.5 ± 28.7* | 65.5 ± 24.6 | 53.5 ± 22.1 |
MIP-1α | 6.4 ± 2.8 | 30.7 ± 10.4* | 17.8 ± 8.9 | 14.5 ± 7.9 |
MIP-1β | 93.7 ± 31.0 | 183.5 ± 19.1* | 160.0 ± 24.5* | 135.5 ± 25.7 |
PDGF | 0.6 ± 0.3 | 2.2 ± 0.5* | 0.4 ± 0.1 | 1.2 ± 0.3 |
RANTES | 6.5 ± 0.9 | 20.3 ± 1.0* | 7.8 ± 1.1 | 7.9 ± 1.0 |
TNF-α | 4.0 ± 1.9 | 19.2 ± 4.5* | 5.3 ± 3.3 | 2.7 ± 1.0 |
VEGF | 7.8 ± 2.6 | 13.3 ± 2.5* | 10.5 ± 3.3 | 10.4 ± 2.8 |
Eosinophils were incubated with CXCR3 ligands for 24 h, and the concentrations of cytokines and chemokines in cell-free supernatants were measured using Bio-plex assay kits. *P < 0.05 versus without CXCR3 ligands.